Literature DB >> 23151683

Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID).

Sheena Grant1, Elaine Cross, James Edmond Wraith, Simon Jones, Louise Mahon, Michelle Lomax, Brian Bigger, Dougal Hare.   

Abstract

Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) is a lysosomal storage disorder, caused by a deficiency in one of four enzymes involved in the catabolism of the glycosaminoglycan heparan sulphate. It is a degenerative disorder, with a progressive decline in children's intellectual and physical functioning. There is currently no cure for the disorder. To date there is a paucity of research on how this disorder impacts parents psychological functioning. Specifically, research in the area has failed to employ adequate control groups to assess if the impact of this disorder on parents psychological functioning differs from parenting a child with intellectual disability (ID). The current study examined child behaviour and parental psychological functioning in 23 parents of children with MPS III and 23 parents of children with ID. Parents completed postal questionnaires about their child's behaviour and abilities and their own psychological functioning. Parents of children with MPS III reported fewer behavioural difficulties as their child aged, more severe level of intellectual disability, and similar levels of perceived social support, coping techniques, stress, anxiety and depression levels as parents of children with ID. Both groups of parents scored above the clinical cut off for anxiety and depression. Parents of children with MPS III rated themselves as significantly less future-orientated and goal directed than parents of children with ID. Services should develop support packages for parents of children with MPS III that incorporate an understanding of the unique stressors and current-difficulty approach of this population. Future research should examine gender differences between parental psychological functioning, using mixed qualitative and quantitative approaches, and utilise matched developmental level and typically developing control groups.

Entities:  

Mesh:

Year:  2012        PMID: 23151683     DOI: 10.1007/s10545-012-9558-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  28 in total

1.  The role of coping in maintaining the psychological well-being of mothers of adults with intellectual disability and mental illness.

Authors:  H W Kim; J S Greenberg; M M Seltzer; M W Krauss
Journal:  J Intellect Disabil Res       Date:  2003 May-Jun

2.  Challenging symptom profiles of life-limiting conditions in children: a survey of care professionals and families.

Authors:  Cari Malcolm; Liz Forbat; Gillian Anderson; Faith Gibson; Richard Hain
Journal:  Palliat Med       Date:  2011-01-12       Impact factor: 4.762

3.  You want to measure coping but your protocol's too long: consider the brief COPE.

Authors:  C S Carver
Journal:  Int J Behav Med       Date:  1997

4.  Behaviour in mucopolysaccharide disorders.

Authors:  M C Bax; G A Colville
Journal:  Arch Dis Child       Date:  1995-07       Impact factor: 3.791

5.  Childhood illness-related parenting stress: the pediatric inventory for parents.

Authors:  R Streisand; S Braniecki; K P Tercyak; A E Kazak
Journal:  J Pediatr Psychol       Date:  2001 Apr-May

6.  Trajectory of certain death at an unknown time: children with neurodegenerative life-threatening illnesses.

Authors:  R G Steele
Journal:  Can J Nurs Res       Date:  2000-12

7.  The validity of two versions of the GHQ in the WHO study of mental illness in general health care.

Authors:  D P Goldberg; R Gater; N Sartorius; T B Ustun; M Piccinelli; O Gureje; C Rutter
Journal:  Psychol Med       Date:  1997-01       Impact factor: 7.723

8.  Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study.

Authors:  F D Nidiffer; T E Kelly
Journal:  J Ment Defic Res       Date:  1983-09

9.  Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands.

Authors:  G J G Ruijter; M J Valstar; J M van de Kamp; R M van der Helm; S Durand; O P van Diggelen; R A Wevers; B J Poorthuis; A V Pshezhetsky; F A Wijburg
Journal:  Mol Genet Metab       Date:  2007-11-19       Impact factor: 4.797

10.  Preventing conduct problems and improving school readiness: evaluation of the Incredible Years Teacher and Child Training Programs in high-risk schools.

Authors:  Carolyn Webster-Stratton; M Jamila Reid; Mike Stoolmiller
Journal:  J Child Psychol Psychiatry       Date:  2008-01-21       Impact factor: 8.982

View more
  18 in total

1.  Coping Strategies, Stress, and Support Needs in Caregivers of Children with Mucopolysaccharidosis.

Authors:  Amy Schadewald; Ericka Kimball; Li Ou
Journal:  JIMD Rep       Date:  2018-01-04

2.  Associations Between Resilience and the Well-Being of Mothers of Children with Autism Spectrum Disorder and Other Developmental Disabilities.

Authors:  Elizabeth Halstead; Naomi Ekas; Richard P Hastings; Gemma M Griffith
Journal:  J Autism Dev Disord       Date:  2018-04

Review 3.  Assessment, pharmacological therapy and rehabilitation management of musculoskeletal pain in children with mucopolysaccharidoses: a scoping review.

Authors:  R Gnasso; B Corrado; I Iommazzo; F Migliore; G Magliulo; B Giardulli; C Ruosi
Journal:  Orphanet J Rare Dis       Date:  2022-07-08       Impact factor: 4.303

4.  Journaling as reinforcement for the resourcefulness training intervention in mothers of technology-dependent children.

Authors:  Valerie Boebel Toly; Julia E Blanchette; Carol M Musil; Jaclene A Zauszniewski
Journal:  Appl Nurs Res       Date:  2016-08-21       Impact factor: 2.257

5.  Parent Experiences of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment.

Authors:  Katherine Ackerman Porter; Cara O'Neill; Elise Drake; Samantha Parker; Maria L Escolar; Stacey Montgomery; William Moon; Carolyn Worrall; Holly L Peay
Journal:  Neurol Ther       Date:  2020-12-02

6.  An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III.

Authors:  Elaine M Cross; Sheena Grant; Simon Jones; Brian W Bigger; James E Wraith; Louise V Mahon; Michelle Lomax; Dougal J Hare
Journal:  J Neurodev Disord       Date:  2014-12-31       Impact factor: 4.025

7.  Parents' experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS).

Authors:  S Somanadhan; P J Larkin
Journal:  Orphanet J Rare Dis       Date:  2016-10-10       Impact factor: 4.123

8.  Experiences of caregivers of children with inherited metabolic diseases: a qualitative study.

Authors:  Shabnaz Siddiq; Brenda J Wilson; Ian D Graham; Monica Lamoureux; Sara D Khangura; Kylie Tingley; Laure Tessier; Pranesh Chakraborty; Doug Coyle; Sarah Dyack; Jane Gillis; Cheryl Greenberg; Robin Z Hayeems; Shailly Jain-Ghai; Jonathan B Kronick; Anne-Marie Laberge; Julian Little; John J Mitchell; Chitra Prasad; Komudi Siriwardena; Rebecca Sparkes; Kathy N Speechley; Sylvia Stockler; Yannis Trakadis; Sarah Wafa; Jagdeep Walia; Kumanan Wilson; Nataliya Yuskiv; Beth K Potter
Journal:  Orphanet J Rare Dis       Date:  2016-12-07       Impact factor: 4.123

9.  Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III.

Authors:  Arunabha Ghosh; Elsa Shapiro; Stewart Rust; Kathleen Delaney; Samantha Parker; Adam J Shaywitz; Adelaida Morte; Gillian Bubb; Maureen Cleary; Tien Bo; Christine Lavery; Brian W Bigger; Simon A Jones
Journal:  Orphanet J Rare Dis       Date:  2017-06-26       Impact factor: 4.123

10.  Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome).

Authors:  Rachel A Mumford; Louise V Mahon; Simon Jones; Brian Bigger; Maria Canal; Dougal Julian Hare
Journal:  J Neurodev Disord       Date:  2015-09-01       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.